| Literature DB >> 34877358 |
Xi Guo1, Su Wang2, Yu-Chen Chen3, Heng-Le Wei1, Gang-Ping Zhou1, Yu-Sheng Yu1, Xindao Yin3, Kun Wang2, Hong Zhang1.
Abstract
Alterations of brain functional connectivity in patients with type 2 diabetes mellitus (T2DM) have been reported by resting-state functional magnetic resonance imaging studies, but the underlying precise neuropathological mechanism remains unclear. This study is aimed at investigating the implicit alterations of functional connections in T2DM by integrating functional connectivity strength (FCS) and Granger causality analysis (GCA) and further exploring their associations with clinical characteristics. Sixty T2DM patients and thirty-three sex-, age-, and education-matched healthy controls (HC) were recruited. Global FCS analysis of resting-state functional magnetic resonance imaging was performed to explore seed regions with significant differences between the two groups; then, GCA was applied to detect directional effective connectivity (EC) between the seeds and other brain regions. Correlations of EC with clinical variables were further explored in T2DM patients. Compared with HC, T2DM patients showed lower FCS in the bilateral fusiform gyrus, right superior frontal gyrus (SFG), and right postcentral gyrus, but higher FCS in the right supplementary motor area (SMA). Moreover, altered directional EC was found between the left fusiform gyrus and bilateral lingual gyrus and right medial frontal gyrus (MFG), as well as between the right SFG and bilateral frontal regions. In addition, triglyceride, insulin, and plasma glucose levels were correlated with the abnormal EC of the left fusiform, while disease duration and cognitive function were associated with the abnormal EC of the right SFG in T2DM patients. These results suggest that T2DM patients show aberrant brain function connectivity strength and effective connectivity which is associated with the diabetes-related metabolic characteristics, disease duration, and cognitive function, providing further insights into the complex neural basis of diabetes.Entities:
Mesh:
Year: 2021 PMID: 34877358 PMCID: PMC8645376 DOI: 10.1155/2021/5171618
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
Demographic and clinical characteristics of the participants.
| Characteristics | Patients with type 2 diabetes ( | Healthy controls ( |
|
|---|---|---|---|
| Demographic factors | |||
| Sex (female/male) | 21/39 | 15/18 | 0.322 |
| Age (years) | 58.10 ± 9.87 | 56.06 ± 7.36 | 0.302 |
| Education (years) | 10.88 ± 3.30 | 11.85 ± 3.07 | 0.120 |
| BMI (kg/m2) | 25.58 ± 3.78 | 24.36 ± 1.82 | 0.102 |
| Diabetes-related characteristics | |||
| Disease duration (months)1 | 72 (0~312) | — | — |
| Onset age (years)1 | 50 (26~72) | — | — |
| HbA1c (%) | 8.35 ± 2.06 | 5.11 ± 0.55 | <0.001∗ |
| Fasting glucose (mmol/L) | 7.5 ± 2.85 | 4.92 ± 0.58 | <0.001∗ |
| 1 h postprandial glucose (mmol/L) | 12.34 ± 2.72( | — | — |
| 2 h postprandial glucose (mmol/L) | 15.06 ± 3.66( | — | — |
| Fasting insulin (pmol/L) | 44.96 ± 32.67 | — | — |
| 1 h postprandial insulin (pmol/L) | 212.06 ± 436.27 ( | — | — |
| 2 h postprandial insulin (pmol/L) | 211.94 ± 144.90 ( | — | — |
| Clinical variables | |||
| Arterial blood pressure | |||
| Systolic BP (mmHg) | 140.28 ± 21.14 | 124 ± 8.9 | <0.001∗ |
| Diastolic BP (mmHg) | 82.12 ± 13.44 | 72.23 ± 7.8 | 0.035 |
| Total cholesterol (mmol/L) | 4.44 ± 0.95 | 4.48 ± 0.53 | 0.094 |
| Triglyceride (mmol/L) | 1.99 ± 1.07 | 1.41 ± 0.20 | <0.001∗ |
| High-density lipoprotein (mmol/L) | 1.07 ± 0.271 | 1.02 ± 0.23 | 0.557 |
| Low-density lipoprotein (mmol/L) | 2.64 ± 0.75 | 3.31 ± 3.00 | 0.118 |
| General cognitive assessment | |||
| MoCA | 28.08 ± 1.25 | 28.5 ± 0.94 | 0.086 |
Data are presented as mean ± SD or medians and interquartile ranges (25th–75th percentiles)1. BMI: body mass index; BP: blood pressure; HbA1c: hemoglobin A1c; MoCA: Montreal Cognitive Assessment; ∗P < 0.05 was considered significant.
Figure 1Group differences in global FCS between patients with type 2 diabetes and healthy controls after correction for GMV (P < 0.001, uncorrected). HC: healthy controls; L: left; R: right; T2DM: type 2 diabetes mellitus.
Brain regions with significant group differences in FCS.
| Regions | Brodmann areas | Cluster size (voxels) | Peak | Coordinates in MNI ( |
|---|---|---|---|---|
|
| ||||
| Fusiform_R | 56 | 34 | 3.8 | 33, -69, -15 |
| Fusiform_L | 55 | 40 | 4.1 | -30, -72, -15 |
| Superior_Frontal_Gyrus_R | 6 | 47 | 4.3 | 12, 51, -21 |
| Postcentral_R | 58 | 71 | 4.3 | 60, -9, 39 |
|
| ||||
| Supp_Motor_Area_R | 20 | 31 | -4.3 | 6, 3, 54 |
FCS: functional connectivity strength; MNI: Montreal Neurological Institute; L: left; R: right.
Figure 2Altered effective connectivity of left fusiform and right superior frontal gyrus in type 2 diabetes compared with healthy control (P < 0.001, uncorrected). IFG: inferior frontal gyrus; L: left; MFG: medial frontal gyrus; R: right; SFG: superior frontal gyrus; SMA: supplementary motor area.
Brain regions with significant group differences in EC.
| Effective connectivity | Cluster size (voxels) | Peak | Coordinates in MNI ( |
|---|---|---|---|
|
| |||
| Lingual_R | 26 | -3.86 | 18, -75, -3 |
| Lingual_L | 108 | -5.18 | -27, -54, -9 |
| Medial_Frontal_Gyrus_R | 27 | 3.76 | 3, 48, -18 |
|
| |||
| Lingual_R | 23 | 3.91 | 18, -75, -3 |
| Lingual_L | 51 | 5.04 | -27, -57, -12 |
| Medial_Frontal_Gyrus_R | 23 | -3.87 | 3, 51, -18 |
|
| |||
| Inferior_Frontal_Gyrus_L | 46 | 4.26 | -45, 15, 18 |
| Medial_Frontal_Gyrus_R | 64 | 4.23 | 9, 30, 39 |
| Supp_Motor_Area_L | 29 | 3.74 | 0, 15, 51 |
|
| |||
| Inferior_Frontal_Gyrus_L | 129 | -4.78 | -18, 39, 27 |
MNI: Montreal Neurological Institute; SFG: superior frontal gyrus L: left; R: right.
Figure 3Significant correlations between abnormal effective connectivity of left fusiform and clinical characteristics in type 2 diabetes (P < 0.05).
Figure 4Significant correlations between abnormal effective connectivity of right superior frontal gyrus and clinical characteristics in type 2 diabetes (P < 0.05). MFG: medial frontal gyrus; MoCA: Montreal Cognitive Assessment; SBP: systolic blood pressure; SFG: superior frontal gyrus; SMA: supplementary motor area.